Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 191-197, February 2009

Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas

  • Hye Kyung Shim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
  • ,
  • Won Woo Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Korea
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Seoul National University Bundang Hospital, Gyeonggi-do 463-707, Korea. Tel.: +82 31 787 7672; fax: +82 31 787 4018.
  • ,
  • So Yeon Park

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
  • ,
  • Haeryoung Kim

      Affiliations

    • Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
  • ,
  • Young So

      Affiliations

    • Department of Nuclear Medicine, Konkuk University School of Medicine, Korea
  • ,
  • Sang Eun Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Korea

Received 1 October 2008; received in revised form 14 November 2008; accepted 21 November 2008.

Abstract 

Introduction

Diffuse large B-cell lymphoma (DLBCL) has been reported to show higher uptake of 2-deoxy-2-F18-fluoro-d-glucose (FDG) by positron emission tomography than other B-cell non-Hodgkin's lymphomas (non-DLBCL). The authors addressed the mechanism of FDG uptake in DLBCL by immunostaining for glucose transporter Types 1 (Glut-1) and 3 (Glut-3) and hexokinase-II (HK-II) in excised lymphoma tissues.

Methods

Sixteen B-cell non-Hodgkin's lymphoma patients (11 DLBCL and 5 non-DLBCL patients) were included in the study because the lymphoma tissues obtained by excision were eligible for immunostaining. The expressions of Glut-1, Glut-3 and HK-II were assessed regarding the percentages of positively stained lymphoma cells (%expression), the staining intensities (none=0, weak=1, moderate=2 and strong=3) and the staining patterns (membranous or cytoplasmic) and compared between DLBCL and non-DLBCL.

Results

Glut-1 was not expressed at all in DLBCL or non-DLBCL, and their Glut-3 expressions were not significantly different (P>.05) with respect to %expression (mean±S.E.M., 73.6±7.3% vs. 72.0±3.7%), staining intensity (2.5±0.2 vs. 2.6±0.2) and staining pattern (membranous pattern dominant; 54.5% vs. 60.0%). However, DLBCL expressed more HK-II than non-DLBCL, i.e., %expression (45.2±11.5% vs. 17.0±15.8%, P=.0275) and staining intensity (2.3±0.2 vs. 0.6±0.4, P=.0032). HK-II showed a cytoplasmic location in DLBCL and non-DLBCL.

Conclusions

HK-II and Glut-3 contribute significantly to FDG uptake in DLBCL. DLBCL may have higher FDG uptake because it expresses more HK-II, whereas Glut-1 appears to play no role in FDG uptake in B-cell non-Hodgkin's lymphoma.

Keywords: Diffuse large B-cell lymphoma, Glucose transporter, Hexokinase, FDG-PET

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2007-331-E00168) and by the Korea Science and Engineering Foundation (KOSEF) Grant funded by the Korean government (MOST) (No. 2008-01386).

PII: S0969-8051(08)00250-3

doi:10.1016/j.nucmedbio.2008.11.009

Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 191-197, February 2009